Beam Therapeutics Stock Year To Date Return
| BEAM Stock | USD 28.81 0.11 0.38% |
Beam Therapeutics fundamentals help investors to digest information that contributes to Beam Therapeutics' financial success or failures. It also enables traders to predict the movement of Beam Stock. The fundamental analysis module provides a way to measure Beam Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Beam Therapeutics stock.
Beam | Year To Date Return |
Beam Therapeutics Company Year To Date Return Analysis
Beam Therapeutics' Year to Date Return (YTD) is the total return generated from holding a security from the beginning of the current fiscal year. In other words, YTD Return represents the capital appreciation of your investments from the start of the current fiscal year.
More About Year To Date Return | All Equity Analysis
YTD Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Beam Year To Date Return Driver Correlations
Understanding the fundamental principles of building solid financial models for Beam Therapeutics is extremely important. It helps to project a fair market value of Beam Stock properly, considering its historical fundamentals such as Year To Date Return. Since Beam Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Beam Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Beam Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Year-To-Date typically refers to a period starting from the beginning of the current year and continuing up to the present day. Investors should becareful when comparing YTD ratios if not much of the year has occurred as research shows that YTD measures are more sensitive to early periods than late.
| Competition |
Beam Return On Tangible Assets
Return On Tangible Assets |
|
In accordance with the company's disclosures, Beam Therapeutics has a Year To Date Return of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Beam Year To Date Return Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Beam Therapeutics' direct or indirect competition against its Year To Date Return to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Beam Therapeutics could also be used in its relative valuation, which is a method of valuing Beam Therapeutics by comparing valuation metrics of similar companies.Beam Therapeutics is currently under evaluation in year to date return category among its peers.
Beam Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Beam Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Beam Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Beam Fundamentals
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0928 | ||||
| Profit Margin | (0.41) % | ||||
| Operating Margin | (7.46) % | ||||
| Current Valuation | 1.61 B | ||||
| Shares Outstanding | 82.81 M | ||||
| Shares Owned By Insiders | 1.40 % | ||||
| Shares Owned By Institutions | 93.08 % | ||||
| Number Of Shares Shorted | 10.68 M | ||||
| Price To Earning | 37.48 X | ||||
| Price To Book | 3.00 X | ||||
| Price To Sales | 6.80 X | ||||
| Revenue | 377.71 M | ||||
| Gross Profit | (250.67 M) | ||||
| EBITDA | (156.47 M) | ||||
| Net Income | (132.53 M) | ||||
| Cash And Equivalents | 1.09 B | ||||
| Cash Per Share | 15.90 X | ||||
| Total Debt | 172.69 M | ||||
| Debt To Equity | 0.25 % | ||||
| Current Ratio | 4.64 X | ||||
| Book Value Per Share | 9.97 X | ||||
| Cash Flow From Operations | (149.19 M) | ||||
| Short Ratio | 8.86 X | ||||
| Earnings Per Share | (1.58) X | ||||
| Price To Earnings To Growth | (2.30) X | ||||
| Target Price | 49.2 | ||||
| Number Of Employees | 472 | ||||
| Beta | 1.86 | ||||
| Market Capitalization | 2.38 B | ||||
| Total Asset | 1.46 B | ||||
| Retained Earnings | (1.19 B) | ||||
| Working Capital | 1.01 B | ||||
| Current Asset | 2.89 B | ||||
| Current Liabilities | 706.6 M | ||||
| Net Asset | 1.46 B |
About Beam Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Beam Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Beam Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Beam Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Beam Therapeutics Piotroski F Score and Beam Therapeutics Altman Z Score analysis. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.58) | Revenue Per Share 4.273 | Quarterly Revenue Growth (0.17) | Return On Assets (0.09) | Return On Equity (0.18) |
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Beam Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.